The Calmer Co. (ASX:CCO) surges in global kava market with record $10m revenue run rate

In a landscape where wellness trends constantly evolve, The Calmer Co. (ASX:CCO) has emerged as a strong player in the global kava market, recently reporting a record-breaking revenue milestone.

This October, the company achieved an impressive monthly revenue of over $860,000, translating to an annualised rate of more than $10 million—a figure that triples the revenue from October 2023.

Highlights:

• Record Sales: $860,000 in October alone, an annualised revenue rate exceeding $10 million.
• E-commerce Expansion: The Amazon USA and Australian Shopify channels accounted for $670,000, averaging daily e-commerce sales of more than $21,500.
• Product Line Diversification: New flavoured kava products, like the Taki Mai shots and kava stick packs, are bolstering the company’s U.S. presence.

Anthony Noble, Managing Director at The Calmer Co., attributes the surge to strategic expansions in e-commerce and an evolving product line-up, particularly in the United States.

“We continue to push through previous record sales results as we enter Q2,” said Noble.

“The October result was driven by eCommerce and Australian retail sales, with our Taki Mai cold press juice shots, mango and peach flavour boosters, and kava drinking accessories all contributing to by far our best month in that channel.”

This growth spurt is well-timed, as the company gears up for a high-spending holiday season. With solid stock levels in place, The Calmer Co. is poised to capitalise on Black Friday, Cyber Monday, and the Christmas shopping wave.

Noble hinted at further momentum in Q2 as additional products roll out in the U.S. market, anticipating a continued upward trajectory.

In addition to organic growth, the company has launched innovative product lines to meet consumer demand for convenience and flavour.

The Taki Mai range, featuring dietary shots and flavour boosters, highlights The Calmer Co.’s commitment to product development, appealing to a broader audience seeking wellness solutions.

As a prominent player in the natural health industry, The Calmer Co.’s diversified product range—including kava powders, teas, shots, and capsules—positions it well for sustained growth.

The company’s ambitious aim to dominate the kava market reflects a strategic approach to capitalising on increasing global demand for natural relaxation aids, particularly in high-stakes markets such as the U.S., Australia, and China.

With eyes set on becoming the world’s leading kava provider, The Calmer Co. is on a trajectory that market watchers would be wise to follow closely.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.